BIOMAT Database Logo BIOMAT Database Logo

Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. 2004

Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Schools of Medicine, University of North Carolina, Chapel Hill 27599-7360, USA.

The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D002584 Cervix Uteri The neck portion of the UTERUS between the lower isthmus and the VAGINA forming the cervical canal. Cervical Canal of the Uterus,Cervical Canal, Uterine,Ectocervix,Endocervical Canal,Endocervix,External Os Cervix,External Os of the Cervix,Uterine Cervical Canal,Cervix,Cervixes,Uterine Cervix,Canal, Endocervical,Canal, Uterine Cervical,Cervix, External Os,Cervix, Uterine,Endocervical Canals,Uterine Cervical Canals
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014621 Vagina The genital canal in the female, extending from the UTERUS to the VULVA. (Stedman, 25th ed) Vaginas
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
October 2010, Therapeutic drug monitoring,
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
April 2009, Journal of acquired immune deficiency syndromes (1999),
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract.
March 2005, Journal of acquired immune deficiency syndromes (1999),
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
October 2004, Current HIV research,
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
April 2012, HIV medicine,
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
September 2013, AIDS (London, England),
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
July 2009, AIDS (London, England),
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
December 2004, The Journal of infectious diseases,
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
October 2020, AIDS (London, England),
Sherene S Min, and Amanda H Corbett, and Naser Rezk, and Susan Cu-Uvin, and Susan A Fiscus, and Leslie Petch, and Myron S Cohen, and Angela D M Kashuba
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
December 1990, Science (New York, N.Y.),
Copied contents to your clipboard!